The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: A meta-analysis

Transplantation Proceedings

Volumn 44, Issue 10, 2012, Pages 2955-2960

  Hao, W J ^a   Zong, H T ^a   Cui, Y S ^a   Zhang, Y ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ARTICLE; BACTERIAL INFECTION; COLITIS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GANGRENE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MENINGITIS; META ANALYSIS; MYCOSIS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PUSTULE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROMA; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; URINARY TRACT INFECTION; URINARY TRACTI NFECTION; VIRUS INFECTION;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; COMMUNICABLE DISEASES; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; ODDS RATIO; PANCREAS TRANSPLANTATION; RISK FACTORS; TIME FACTORS; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84870153624     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.05.085     Document Type: Article

References (12)

1. M.L. Barr, J. Belghiti, F.G. Villamil A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines Transplantation 81 2006 1373
2. Y. Liu, P. Zhou, M. Han Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis Transplant Proc 42 2010 1667
3. R. Martin Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis Neurodegener Dis 5 2008 23
4. A. Farney, A. Sundberg, P. Moore A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation Clin Transplant 22 2008 41
5. A.C. Farney, W. Doares, J. Rogers A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation Transplantation 88 2009 810
6. P.G. Thomas, K.J. Woodside, J.A. Lappin Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation Transplantation 83 2007 1509
7. M.J. Hanaway, E.S. Woodle, S. Mulgaonkar Alemtuzumab induction in renal transplantation N Engl J Med 364 2011 1909
8. T.M. Lü, S.L. Yang, W.Z. Wu Alemtuzumab induction therapy in highly sensitized kidney transplant recipients Chin Med J (Engl) 124 2011 664
9. G. Ciancio, G.W. Burke, J.J. Gaynor A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up Clin Transplant 22 2008 200
10. G. Ciancio, J.J. Gaynor, D. Roth Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation Transplant Proc 42 2010 3503
11. R. Abou-Ayache, M. Büchler, P. Lepogamp CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A Nephrol Dial Transplant 23 2008 2024
12. V.A. Huurman, J.S. Kalpoe, P. van de Linde Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kid ney transplant recipients Diabetes Care 29 2006 842